Business Context and Reporting Period
Company: Canopy Growth Corp (CGC)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Nine months ended December 31, 2024 (Fiscal Q3 2025)
Business Overview: Canopy Growth is a global cannabis company producing and selling cannabis products for adult-use and medical purposes in Canada, Europe, and Australia. The company also operates the Storz & Bickel vaporizer business. A significant portion of the filing details the strategic reorganization of its U.S. operations through Canopy USA, LLC, including the deconsolidation of Canopy USA and the acquisition of Acreage Holdings, Inc.
Key Financial Metrics
| Metric (CAD in thousands) | Three Months Ended Dec 31, 2024 | Nine Months Ended Dec 31, 2024 | Nine Months Ended Dec 31, 2023 |
|---|---|---|---|
| Net Revenue | $74,761 | $203,964 | $224,358 |
| Gross Margin | $24,098 (32%) | $68,967 (34%) | $65,414 (29%) |
| Operating Loss | $(23,822) | $(98,873) | $(121,975) |
| Net Loss (Continuing Ops) | $(121,896) | $(382,637) | $(389,007) |
| Net Loss Per Share (Diluted) | $(1.11) | $(4.15) | $(5.56) |
| Cash and Cash Equivalents | $161,909 | $161,909 | $142,745 |
| Total Debt (Principal) | $459,800 | $459,800 | $622,000 |
| Free Cash Flow | $(28,181) | $(140,322) | $(209,161) |
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 5% year-over-year (Q3) and 9% year-over-year (YTD). The decline is driven by lower adult-use cannabis sales in Canada due to price competition and the divestiture of the "This Works" segment in late 2023. This was partially offset by growth in medical cannabis and international markets.
- Improved Margins: Gross margin percentage improved to 34% YTD from 29% in the prior year, attributed to cost savings programs, reduced inventory write-downs, and a shift to higher-margin medical sales.
- Reduced Operating Loss: Operating loss narrowed significantly to $98.9 million YTD from $122.0 million in the prior year, driven by a 25% reduction in SG&A expenses and lower restructuring charges compared to the prior year.
- Debt Reduction: Total debt principal decreased by approximately $162 million year-over-year due to significant paydowns of the Credit Facility and the exchange of the CBI Note for equity.
- Non-GAAP Fair Value Volatility: Net loss was heavily impacted by non-cash fair value adjustments on financial assets (Canopy USA, Acreage, TerrAscend), totaling an expense of $277.0 million YTD.
Guidance, Outlook, and Risks
- Going Concern: Management states that substantial doubt regarding the company's ability to continue as a going concern has been alleviated following balance sheet deleveraging, equity issuances, and debt restructuring.
- Canopy USA Strategy: The company deconsolidated Canopy USA effective April 30, 2024, to comply with Nasdaq listing rules. Canopy USA now holds 100% of Acreage, Wana, and a majority stake in Jetty. Canopy Growth holds non-voting shares in Canopy USA, which are convertible only upon U.S. federal cannabis legalization.
- Equity Financing: The company established an At-The-Market (ATM) program, selling approximately 39.5 million shares for $256 million in gross proceeds during the nine-month period.
- Key Risks:
- Acreage Going Concern: Acreage's financial statements express doubt about its ability to continue as a going concern. Canopy Growth holds significant debt exposure to Acreage (approx. $106 million principal), which is subordinate to other lenders.
- Regulatory/Legal: Ongoing SEC investigation regarding the BioSteel revenue restatement and related class action litigation (though a U.S. class action was recently dismissed).
- Market Conditions: Continued price competition in the Canadian adult-use market and regulatory uncertainty in the U.S.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the amended Credit Facility covenants, specifically the minimum liquidity requirements and interest coverage ratios.
- Acreage Solvency: Monitor Acreage's ability to service its debt obligations, as Canopy Growth's investment in Canopy USA is heavily tied to Acreage's performance and solvency.
- Equity Dilution: Track the pace of share issuances under the ATM program and the potential dilution from the conversion of the May 2024 Convertible Debenture and outstanding warrants.
- Legal Proceedings: Review the status of the SEC investigation regarding BioSteel and any potential financial penalties or restatement impacts.
- Canopy USA Conversion: Assess the likelihood and timeline of U.S. federal cannabis legalization, which is the trigger for converting Canopy Growth's non-voting shares into economic equity in Canopy USA.